Skip to main content

09-11-2020 | ACR 2020 | Conference coverage | Video

FAST trial suggests comparable CV safety of febuxostat vs allopurinol

Investigator Fernando Pérez-Ruiz talks about the results of the FAST trial, showing no increase in the risk for cardiovascular events with febuxostat versus allopurinol treatment in patients with gout (4:14).

Read transcript